Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK1 | Q15118 | 15/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | NSD2 | O96028 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3056327 | 0.78 | PDK1 (0.55) | PDK1GAATSHRNPC1ALDH1A1 | |
| SCHEMBL19411231 | 0.77 | ACVR1 (0.43) | GAATSHRALDH1A1GLASMN1; SMN2 | |
| SCHEMBL3061506 | 0.77 | RAB9A (0.55) | PDK1GAATSHRNPC1ALDH1A1 | |
| SCHEMBL3058847 | 0.76 | PDK1 (0.50) | PDK1GAATSHRNPC1ALDH1A1 | |
| SCHEMBL2404534 | 0.75 | NR2E1 (0.41) | GAANSD2NPC1ALDH1A1RAB9A | |
| SCHEMBL1927016 | 0.75 | ALDH1A1 (0.69) | PDK1GAATSHRNPC1ALDH1A1 | |
| SCHEMBL8568156 | 0.74 | PREP (0.47) | GAATSHRNSD2ALDH1A1GLA | |
| SCHEMBL28859700 | 0.74 | HDAC3 (0.43) | NSD2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL17927686 | 0.74 | RAB9A (0.54) | GAANSD2NPC1RAB9ASMN1; SMN2 | |
| Biphenyl SCHEMBL27669531 | 0.74 | NSD2 (0.44) | PDK1NSD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100261758-A1 | HETEROCYCLIC AMIDES FOR USE AS PHARMACEUTICALS | NOVARTIS AG (CH) | 2010-10-14 | — | — | US | disclosed |
| EP-2001851-A2 | AMIDE DERIVATIVES AND THEIR APPLICATION FOR THE TREAMENT OF G PROTEIN RELATED DISEASES | Novartis AG (CH) | 2008-12-17 | — | — | EP | disclosed |
| WO-2007110237-A2 | AMIDE DERIVATIVES AND THEIR APPLICATION FOR THE TREATMENT OF G PROTEIN RELATED DISEASES | NOVARTIS AG (CH) | 2007-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261758-A1 | HETEROCYCLIC AMIDES FOR USE AS PHARMACEUTICALS | HRH4, CNR1, CNR2 | PDK1 2335/4885GAA 1212/4885TSHR 384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.